AUPH
Aurinia Pharmaceuticals Inc.$16.05-0.37 (-2.25%)Prev Close$16.41·MCap$2.11B·P/E7.75·Vol602.4K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
13
$7.51M
◆
Net Activity
Net Seller
$7.51M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Aurinia Pharmaceuticals Inc. (AUPH) has been exclusively selling, with 0 insider purchases totaling $0.00 and 13 insider sales totaling $7.51M. The most recent insider transaction was by Robertson Stephen P. (officer: Chief Legal Officer), who sold $190.4K worth of shares on Sep 11, 2026. Aurinia Pharmaceuticals Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $2.11B.
AUPH Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Robertson Stephen P. | officer: Chief Legal Officer | Sell | 11,939 | $15.95 | $190.4K | 588,848 |
| Aug 25, 2026 | Robertson Stephen P. | officer: Chief Legal Officer | Sell | 20,975 | $16.97 | $355.9K | 600,787 |
| Feb 20, 2026 | Donley Matthew Maxwell | Chief Operating Officer | Sell | 32,901 | $14.40 | $473.8K | 0 |
| Feb 20, 2026 | Greenleaf Peter | Chief Executive Officer | Sell | 100,171 | $14.40 | $1.44M | 0 |
| Feb 20, 2026 | Miller Joseph M | Chief Financial Officer | Sell | 32,424 | $14.40 | $466.9K | 0 |
| Feb 20, 2026 | Robertson Stephen P. | EVP, General Counsel | Sell | 34,638 | $14.40 | $498.8K | 0 |
| Feb 2, 2026 | Keenan Greg | SVP, Chief Medical Officer | Sell | 11,552 | $14.53 | $167.9K | 0 |
| Jan 2, 2026 | Donley Matthew Maxwell | Chief Operating Officer | Sell | 42,787 | $15.95 | $682.5K | 0 |
| Jan 2, 2026 | Greenleaf Peter | Chief Executive Officer | Sell | 113,169 | $15.95 | $1.81M | 0 |
| Jan 2, 2026 | Miller Joseph M | Chief Financial Officer | Sell | 40,161 | $15.95 | $640.6K | 0 |
| Jan 2, 2026 | Robertson Stephen P. | EVP, General Counsel | Sell | 40,385 | $15.95 | $644.1K | 0 |
| Nov 21, 2025 | Bailey Jeffrey Allen | Director | Sell | 2,716 | $15.68 | $42.6K | 0 |
| Nov 21, 2025 | Johnson Craig A | Director | Sell | 6,039 | $15.68 | $94.7K | 0 |
| Aug 1, 2025 | Keenan Greg | Chief Medical Officer | Sell | 20,000 | $10.50 | $210.0K | 0 |
| Aug 1, 2025 | TANG KEVIN | Director | Buy | 1,300,000 | $10.45 | $13.59M1.0% OS | 0 |
| Mar 7, 2025 | Keenan Greg | Chief Medical Officer | Sell | 8,305 | $8.23 | $68.4K | 0 |
| Feb 28, 2025 | Donley Matthew Maxwell | Chief Operating Officer | Sell | 124,893 | $7.96 | $994.4K | 0 |
| Feb 28, 2025 | Greenleaf Peter | Chief Executive Officer | Sell | 360,540 | $7.96 | $2.87M | 0 |
| Feb 28, 2025 | Keenan Greg | Chief Medical Officer | Sell | 12,239 | $8.00 | $97.9K | 0 |
| Feb 28, 2025 | Miller Joseph M | Chief Financial Officer | Sell | 118,013 | $7.96 | $939.6K | 0 |
| Feb 28, 2025 | Robertson Stephen P. | EVP, General Counsel | Sell | 122,479 | $7.96 | $975.2K | 0 |
| Feb 28, 2025 | TANG KEVIN | Director | Buy | 1,600,000 | $7.95 | $12.71M1.2% OS | 0 |
| Dec 5, 2024 | TANG KEVIN | Director | Buy | 1,200,000 | $9.02 | $10.82M0.9% OS | 0 |
| Nov 8, 2024 | Bailey Jeffrey Allen | Director | Sell | 4,557 | $8.43 | $38.4K | 0 |
| Nov 8, 2024 | Smith Karen L. | Director | Sell | 5,241 | $8.43 | $44.2K | 0 |
| Aug 6, 2024 | Habig Scott Michael | Chief Commercial Officer | Sell | 18,249 | $5.31 | $96.9K | 0 |
| May 21, 2024 | Balakrishnan Brinda | Director | Sell | 520 | $5.74 | $3.0K | 0 |
| May 21, 2024 | Billen Daniel | Director | Sell | 5,252 | $5.74 | $30.1K | 0 |
| May 21, 2024 | Jayne David R.W. | Director | Sell | 4,946 | $5.74 | $28.4K | 0 |
| May 21, 2024 | Leversage Jill | Director | Sell | 5,610 | $5.74 | $32.2K | 0 |
| May 21, 2024 | MacKay-Dunn R. Hector | Director | Sell | 5,630 | $5.74 | $32.3K | 0 |
| Mar 6, 2024 | Donley Matthew Maxwell | EVP, Ops & Strategy | Sell | 40,665 | $5.51 | $224.1K | 0 |
| Mar 6, 2024 | Greenleaf Peter | Chief Executive Officer | Sell | 126,981 | $5.60 | $711.1K | 0 |
| Mar 6, 2024 | Habig Scott Michael | Chief Commercial Officer | Sell | 17,777 | $5.60 | $99.6K | 0 |
| Mar 6, 2024 | Miller Joseph M | Chief Financial Officer | Sell | 34,811 | $5.60 | $194.9K | 0 |
| Mar 6, 2024 | Robertson Stephen P. | EVP, General Counsel | Sell | 57,745 | $5.60 | $323.4K | 0 |
| Feb 27, 2024 | Knappertz Volker | EVP, Research and Development | Sell | 4,930 | $6.10 | $30.1K | 0 |
| Feb 20, 2024 | Habig Scott Michael | Chief Commercial Officer | Sell | 15,867 | $5.48 | $87.0K | 0 |
| Feb 20, 2024 | Knappertz Volker | EVP, Research and Development | Sell | 25,146 | $5.48 | $137.8K | 0 |
| May 18, 2023 | Billen Daniel | Director | Sell | 4,650 | $11.26 | $52.4K | 0 |
| May 18, 2023 | Hagan Joseph P | Director | Sell | 272 | $10.58 | $2.9K | 0 |
| May 18, 2023 | Jayne David R.W. | Director | Sell | 8,733 | $11.26 | $98.3K | 0 |
| May 18, 2023 | Leversage Jill | Director | Sell | 4,815 | $11.26 | $54.2K | 0 |
| May 18, 2023 | MacKay-Dunn R. Hector | Director | Sell | 4,818 | $11.26 | $54.3K | 0 |
| Mar 2, 2023 | Greenleaf Peter | Chief Executive Officer | Sell | 32,750 | $8.94 | $292.8K | 0 |
| Mar 2, 2023 | Miller Joseph M | Chief Financial Officer | Sell | 11,296 | $8.94 | $101.0K | 0 |
| Mar 2, 2023 | MILNE GEORGE M JR | Director | Buy | 20,000 | $8.91 | $178.3K | 0 |
| Mar 2, 2023 | Robertson Stephen P. | EVP, General Counsel | Sell | 19,402 | $8.94 | $173.5K | 0 |
| Nov 21, 2022 | Donley Matthew Maxwell | Ex VP, Internal Operations | Buy | 10,000 | $4.66 | $46.6K | 0 |
| Nov 9, 2022 | Habig Scott Michael | Chief Commercial Officer | Buy | 5,000 | $5.02 | $25.1K | 0 |
Showing 1–50 of 86
1 / 2
AUPH Insider Buying Activity
The following table shows recent insider purchases of Aurinia Pharmaceuticals Inc. (AUPH) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | TANG KEVIN | Director | Buy | 1,300,000 | $10.45 | $13.59M1.0% OS | 0 |
| Feb 28, 2025 | TANG KEVIN | Director | Buy | 1,600,000 | $7.95 | $12.71M1.2% OS | 0 |
| Dec 5, 2024 | TANG KEVIN | Director | Buy | 1,200,000 | $9.02 | $10.82M0.9% OS | 0 |
| Mar 2, 2023 | MILNE GEORGE M JR | Director | Buy | 20,000 | $8.91 | $178.3K | 0 |
| Nov 21, 2022 | Donley Matthew Maxwell | Ex VP, Internal Operations | Buy | 10,000 | $4.66 | $46.6K | 0 |
| Nov 9, 2022 | Habig Scott Michael | Chief Commercial Officer | Buy | 5,000 | $5.02 | $25.1K | 0 |
AUPH Insider Selling Activity
The following table shows recent insider sales of Aurinia Pharmaceuticals Inc. (AUPH) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Robertson Stephen P. | officer: Chief Legal Officer | Sell | 11,939 | $15.95 | $190.4K | 588,848 |
| Aug 25, 2026 | Robertson Stephen P. | officer: Chief Legal Officer | Sell | 20,975 | $16.97 | $355.9K | 600,787 |
| Feb 20, 2026 | Donley Matthew Maxwell | Chief Operating Officer | Sell | 32,901 | $14.40 | $473.8K | 0 |
| Feb 20, 2026 | Greenleaf Peter | Chief Executive Officer | Sell | 100,171 | $14.40 | $1.44M | 0 |
| Feb 20, 2026 | Miller Joseph M | Chief Financial Officer | Sell | 32,424 | $14.40 | $466.9K | 0 |
| Feb 20, 2026 | Robertson Stephen P. | EVP, General Counsel | Sell | 34,638 | $14.40 | $498.8K | 0 |
| Feb 2, 2026 | Keenan Greg | SVP, Chief Medical Officer | Sell | 11,552 | $14.53 | $167.9K | 0 |
| Jan 2, 2026 | Donley Matthew Maxwell | Chief Operating Officer | Sell | 42,787 | $15.95 | $682.5K | 0 |
| Jan 2, 2026 | Greenleaf Peter | Chief Executive Officer | Sell | 113,169 | $15.95 | $1.81M | 0 |
| Jan 2, 2026 | Miller Joseph M | Chief Financial Officer | Sell | 40,161 | $15.95 | $640.6K | 0 |
| Jan 2, 2026 | Robertson Stephen P. | EVP, General Counsel | Sell | 40,385 | $15.95 | $644.1K | 0 |
| Nov 21, 2025 | Bailey Jeffrey Allen | Director | Sell | 2,716 | $15.68 | $42.6K | 0 |
| Nov 21, 2025 | Johnson Craig A | Director | Sell | 6,039 | $15.68 | $94.7K | 0 |
| Aug 1, 2025 | Keenan Greg | Chief Medical Officer | Sell | 20,000 | $10.50 | $210.0K | 0 |
| Mar 7, 2025 | Keenan Greg | Chief Medical Officer | Sell | 8,305 | $8.23 | $68.4K | 0 |
| Feb 28, 2025 | Donley Matthew Maxwell | Chief Operating Officer | Sell | 124,893 | $7.96 | $994.4K | 0 |
| Feb 28, 2025 | Greenleaf Peter | Chief Executive Officer | Sell | 360,540 | $7.96 | $2.87M | 0 |
| Feb 28, 2025 | Keenan Greg | Chief Medical Officer | Sell | 12,239 | $8.00 | $97.9K | 0 |
| Feb 28, 2025 | Miller Joseph M | Chief Financial Officer | Sell | 118,013 | $7.96 | $939.6K | 0 |
| Feb 28, 2025 | Robertson Stephen P. | EVP, General Counsel | Sell | 122,479 | $7.96 | $975.2K | 0 |
| Nov 8, 2024 | Bailey Jeffrey Allen | Director | Sell | 4,557 | $8.43 | $38.4K | 0 |
| Nov 8, 2024 | Smith Karen L. | Director | Sell | 5,241 | $8.43 | $44.2K | 0 |
| Aug 6, 2024 | Habig Scott Michael | Chief Commercial Officer | Sell | 18,249 | $5.31 | $96.9K | 0 |
| May 21, 2024 | Balakrishnan Brinda | Director | Sell | 520 | $5.74 | $3.0K | 0 |
| May 21, 2024 | Billen Daniel | Director | Sell | 5,252 | $5.74 | $30.1K | 0 |
| May 21, 2024 | Jayne David R.W. | Director | Sell | 4,946 | $5.74 | $28.4K | 0 |
| May 21, 2024 | Leversage Jill | Director | Sell | 5,610 | $5.74 | $32.2K | 0 |
| May 21, 2024 | MacKay-Dunn R. Hector | Director | Sell | 5,630 | $5.74 | $32.3K | 0 |
| Mar 6, 2024 | Donley Matthew Maxwell | EVP, Ops & Strategy | Sell | 40,665 | $5.51 | $224.1K | 0 |
| Mar 6, 2024 | Greenleaf Peter | Chief Executive Officer | Sell | 126,981 | $5.60 | $711.1K | 0 |
| Mar 6, 2024 | Habig Scott Michael | Chief Commercial Officer | Sell | 17,777 | $5.60 | $99.6K | 0 |
| Mar 6, 2024 | Miller Joseph M | Chief Financial Officer | Sell | 34,811 | $5.60 | $194.9K | 0 |
| Mar 6, 2024 | Robertson Stephen P. | EVP, General Counsel | Sell | 57,745 | $5.60 | $323.4K | 0 |
| Feb 27, 2024 | Knappertz Volker | EVP, Research and Development | Sell | 4,930 | $6.10 | $30.1K | 0 |
| Feb 20, 2024 | Habig Scott Michael | Chief Commercial Officer | Sell | 15,867 | $5.48 | $87.0K | 0 |
| Feb 20, 2024 | Knappertz Volker | EVP, Research and Development | Sell | 25,146 | $5.48 | $137.8K | 0 |
| May 18, 2023 | Billen Daniel | Director | Sell | 4,650 | $11.26 | $52.4K | 0 |
| May 18, 2023 | Hagan Joseph P | Director | Sell | 272 | $10.58 | $2.9K | 0 |
| May 18, 2023 | Jayne David R.W. | Director | Sell | 8,733 | $11.26 | $98.3K | 0 |
| May 18, 2023 | Leversage Jill | Director | Sell | 4,815 | $11.26 | $54.2K | 0 |
| May 18, 2023 | MacKay-Dunn R. Hector | Director | Sell | 4,818 | $11.26 | $54.3K | 0 |
| Mar 2, 2023 | Greenleaf Peter | Chief Executive Officer | Sell | 32,750 | $8.94 | $292.8K | 0 |
| Mar 2, 2023 | Miller Joseph M | Chief Financial Officer | Sell | 11,296 | $8.94 | $101.0K | 0 |
| Mar 2, 2023 | Robertson Stephen P. | EVP, General Counsel | Sell | 19,402 | $8.94 | $173.5K | 0 |
AUPH Insiders
Similar Stocks to AUPH
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B